Zyngenia is a technology company.
Zyngenia has raised $25.0M across 1 funding round.
Zyngenia has raised $25.0M in total across 1 funding round.
Zyngenia has raised $25.0M in total across 1 funding round.
Zyngenia Inc. is a biotherapeutics company developing innovative multi-specific and multi-valent biotherapeutics called Zybodies™ to address unmet needs in inflammation and cancer treatment. The company engineers single molecular entities that interact with two or more targets using proprietary patented technology, focusing on well-validated targets in neoplasms and autoimmune disorders.[1][2][4][5] It has advanced three programs into preclinical development, achieving proof-of-concept with bi-specific and tri-specific Zybodies, including candidates like tri-specific anti-Her1/Her3 Zybody (targeting EGFR for neoplasms) and Adalimumab/anti-Ang2 Zybody (targeting Ang2 and TNF-α for inflammation), all currently in discovery or preclinical stages.[1][3]
Zyngenia serves patients with cancers and autoimmune diseases by solving challenges in traditional monoclonal antibody therapies through superior multi-target engagement, potentially offering more effective treatments.[2][5][6] Incorporated in 2008 and based in Gaithersburg, Maryland, the company maintains a pipeline emphasizing antibody drug conjugates (ADCs) and targeted inhibitors like Ang2 and EGFR antagonists.[3][5]
Zyngenia Inc. was incorporated in 2008 in Gaithersburg, Maryland, establishing itself as a biotech focused on next-generation biotherapeutics.[5] While specific founders are not detailed in available sources, the company emerged from advancements in protein engineering to create multi-specific molecules, addressing limitations of single-target therapies for complex diseases like cancer and autoimmunity.[4][5] Early pivotal moments include applying its proprietary technology to build a pipeline of Zybodies™, with preclinical proof-of-concept demonstrated in inflammation and oncology programs, advancing three candidates into development.[1]
This foundation reflects a strategic pivot toward multi-valent biotherapeutics, leveraging patented platforms to generate innovative entities like bi-specific and tri-specific formats that showed early efficacy in validated models.[1][4]
Zyngenia stands out in the biotherapeutics field through these key strengths:
Zyngenia rides the wave of multi-specific antibody therapeutics, a booming trend in biotech driven by demands for more precise, potent treatments in oncology and immunology. This timing aligns with market forces favoring biologics that overcome resistance in single-target therapies, as seen in rising investments in bispecifics and ADCs amid a projected $100B+ biologics market.[1][3] Favorable dynamics include advances in protein engineering and AI-aided design, enabling Zyngenia's patented platform to tackle hard-to-drug targets like EGFR and Ang2 combinations.[4]
The company influences the ecosystem by validating multi-valent formats in preclinical models, potentially accelerating industry shifts toward poly-specific drugs that improve efficacy and reduce side effects in inflammation and cancer.[1][2][5]
Zyngenia is poised for pipeline progression, with preclinical assets potentially entering IND stages amid surging demand for multi-specific biologics. Trends like ADC expansion and bispecific approvals (e.g., in oncology) will shape its path, bolstered by its Gaithersburg base in a biotech hub.[3][5] Influence may grow through partnerships or funding as proof-of-concept data attracts big pharma, evolving from early-stage innovator to clinical contender in addressing unmet needs with Zybodies™.[1][2] This positions Zyngenia as a watchlist player in precision biotherapeutics.
Zyngenia has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in September 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2010 | $25.0M Series A |